Time |
Room |
|
Activity |
08:15-10:30 | Room 1 | SESSION 3: DIFFUSE GLIOMASModerator: Joab Alves Nicacio Junior (SP) Moderator: Gustavo Matos (DF) 15 | Cannabinoids in glioma treatment 15 | How should be clinical and cognitive assessment in neurooncology? 15 | Advances in patients specific brain mapping strategies 15 | Is there any role for radiosurgery in recurrent gliomas? 15 | The role of re-resection for recurrent IDHwt gliomas 15 | Neuroplasticity and neuroprotection under the radiation oncologist view 15 | Is dexamethasone still the best friend of neuro oncologist? 30 | Discussion |
08:15-10:30 | Room 2 | SESSION 3: SKULL BASE TUMORS 15 | Update on the genetics of pituitary adenomas and a glimpse of the future 15 | Multimodal non-surgical treatments of aggressive pituitary tumors 15 | Advancements in pituary surgery for optimal outcomes 15 | Surgical frontiers: advancements in treating craniopharyngiomas 15 | Confronting recurrence: latest insights in treatment of craniopharyngiomas 15 | Vestibular schwannomas: effectiveness and complications of SRS 15 | Vestibular schwannomas: effectiveness and complications of mircosurgery 30 | Discussion |
08:15-10:30 | Room 3 | SESSION 3: PEDIATRIC SUPRATENTORIAL , MIDLINE TUMORS II AND OTHERS 15 | Radiogenomics in pediatric neuro-oncologySpeaker: Luis Filipe de Souza Godoy (SP) 15 | Managment of pineal Tumors: A surgeon perspectiveSpeaker: Sergio Cavalheiro (SP) 15 | New perspectives for the treatment of intracranial Germ cell tumors 15 | Integrative approach in pediatric craniopharyngeoma managementSpeaker: Sergio Cavalheiro (SP) 15 | Choroid plexus tumors: How to treat properly? 15 | Paliative care in pediatric neuro-oncology: What is the best timing? 45 | CASE DISCUSSION PRESENTATIONPanelist: Frederico Adolfo Benevides Silva (SP) |
10:30-10:50 | Room 1 | BREAK |
10:30-10:50 | Room 2 | BREAK |
10:30-10:50 | Room 3 | BREAK |
10:50-12:00 | Room 1 | PLENARY SESSION 3 10 | Opening Session 20 | Tumor Treating Fields: current role and future directions 20 | Vaccines and IDHwt gliomas: prospects on the horizon 20 | DNA methilation profiling as a model for precision diagnosis in neurooncology |
10:50-12:00 | Room 2 | PLENARY SESSION 3 - ROOM 1 |
10:50-12:00 | Room 3 | PLENARY SESSION 3 - ROOM 1 |
12:00-12:15 | Room 1 | BREAK |
12:00-12:15 | Room 2 | BREAK |
12:00-12:15 | Room 3 | BREAK |
12:15-13:15 | Room 1 | NEW FRONTIRES IN LGG TREATMENT 10 | LGG Clinical case 15 | Navigating Low-Grade Glioma for Neurosurgeons: Key Decision Factors and Clinical Approaches 20 | Translating recent clinical evidence in LGG into clinical practice 15 | Q&A |
12:15-13:15 | Room 2 | ELEMENTS SOFTWARE: NEW SRS TOOLS FOR PLANNING AND FOLLOW UP IN NEURONCOLOGYSpeaker: João Gabriel Ribeiro (SP) |
12:15-13:15 | Room 3 | Duração: 15 min. Duração: 15 min. Duração: 15 min. |
13:15-13:30 | Room 1 | BREAK |
13:15-13:30 | Room 2 | BREAK |
13:15-13:30 | Room 3 | BREAK |
13:30-15:30 | Room 1 | SESSION 4: DIFFUSE GLIOMAS 15 | A Critical Overview of Targeted Therapies for Glioma 15 | Translational research for gliomas: future landscapes and emerging paradigm 15 | The role of CAR T cell therapy in neurooncology 15 | What we do know about non-standard of care treatments for gliomas: cannabis, antidepressants, metformin and others 15 | Bevacizumab, is there still a role for antiangiogenics in glioblastoma? 15 | The optimal timing of palliative care in glioma patients 15 | How feasible is surgery in the motor area? 15 | Discussion |
13:30-15:30 | Room 2 | SESSION 4: METASTASIS 15 | Clinical and radiological assessment in patients with brain metastasisSpeaker: Victor Hugo Rocha Marussi (SP) 15 | Modern concepts of surgery for brain metastasis 15 | Modern concepts of radiosurgery for brain metastasis 15 | Is there still a role for whole-brain radiation therapy for brain metastasis? 15 | Integrative treatment for melanoma brain metastasis 15 | Integrative treatment for lung cancer brain metastasis 15 | Integrative treatment for breast cancer brain metastasis 15 | Discussion |
13:30-15:30 | Room 3 | SESSION 4: PRESENT - FUTURE 15 | Is proton beam therapy a real deal in pediatric neurooncology? 15 | Pre-clinical studies in medulloblastoma: what is new? 15 | Genetic Predisposition Syndromes: How new molecular technologies can help us in the diagnosis and treatment 15 | When does Precision Medicine make a difference in the treatment of our pediatric patients with brain tumors? 15 | The Medulloblastoma initiative- 15 | Liquid biopsy for pediatric neurooncology tumors. Is it possible? 15 | Study Protocol and Perspectives: Embryonal Tumors in infants 15 | Discussion |
15:30-15:50 | Room 1 | BREAK |
15:30-15:50 | Room 2 | BREAK |
15:30-15:50 | Room 3 | BREAK |
15:50-17:30 | Room 1 | PLENARY SESSION 4 20 | Medulloblastoma treatment in children and adolescents: From radiogenomics to molecular biology 20 | Intracranial Germ cell tumors: North American or European, What is the best approach? 20 | Immunotherapy in gliomas: is there a path ahead? 20 | Oncolytic viruses for treatment of gliomas 20 | Is Vorasidenib a real deal for IDHmt gliomas? |
15:50-17:30 | Room 2 | PLENARY SESSION 4 - ROOM 1 |
15:50-17:30 | Room 3 | PLENARY SESSION 4 - ROOM 1 |
17:30-18:30 | Room 1 | 30 | Oral Presentations 20 | Absracts Awards 10 | Acknowledgement and Closure
access abstracts |
17:30-18:30 | Room 2 | ORAL PRESENTATIONS AND ABSTRACTS AWARDS - ROOM 1 |
17:30-18:30 | Room 3 | ORAL PRESENTATIONS AND ABSTRACTS AWARDS - ROOM 1 |